Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer. Pei YY. JAMA 2025 Apr 23. doi: 10.1001/jama.2025.1291.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pei YY. Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer. JAMA 2025 Apr 23. doi: 10.1001/jama.2025.1291.
PMID: 40266585